Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsRDPTF Equity-to-Asset is 0.52 as of Jun. 2025, which is 7% below its 10-year median of 0.56. The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Radiopharm Theranostics ranks worse than 65.89% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Radiopharm Theranostics Equity-to-Asset Related Terms
Radiopharm Theranostics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDPTF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Radiopharm Theranostics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics (RDPTF) has a Equity-to-Asset of 0.52 as of Jun. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Radiopharm Theranostics and its competitors. This is near median its historical median of 0.56. Over the past decade, Radiopharm Theranostics' Equity-to-Asset has ranged from 0.39 to 0.76. According to the industry distribution chart, Radiopharm Theranostics ranks #933 out of 1416 companies in the Biotechnology industry, placing it in the top 65.9%.
Is Radiopharm Theranostics' Equity-to-Asset too high?
Radiopharm Theranostics' current Equity-to-Asset of 0.52 is near median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 0.76. The Biotechnology industry median Equity-to-Asset is 0.68. Radiopharm Theranostics' value of 0.52 is 23.5% below this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #933 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint.
How does Radiopharm Theranostics' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #933 out of 1416 companies for Equity-to-Asset. This places Radiopharm Theranostics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Radiopharm Theranostics' value of 0.52 is 23.5% below this benchmark. Historically, Radiopharm Theranostics' own Equity-to-Asset has ranged from 0.39 to 0.76 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 0.68, Radiopharm Theranostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current Equity-to-Asset of 0.52 is 23.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Equity-to-Asset is 0.52, which is near median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (RDPTF) has a current Equity-to-Asset of 0.52. The current Equity-to-Asset is 0.52, which is near median its 10-year median of 0.56 and 23.5% below the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Radiopharm Theranostics (RDPTF), the current Equity-to-Asset is 0.52 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDPTF has been successfully added to your 
